Cat. No. 4026
Chemical Name: 5-[[4-(4-Pyridinyl)-6-quinolinyl]me
Biological ActivityPotent inhibitor of PI 3-kinase α (PI3Kα) (IC50 = 2 nM). Inhibits proliferation in BT474 cells and attenuates MAPK signaling.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Knight et al (2010) Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med.Chem.Lett. 1 39.
Saadia et al (2009) Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin.Cancer Res. 15 3029. PMID: 19383818.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GSK 1059615 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GSK 1059615, supplier, Potent, inhibitors, inhibits, PI3Kα, PI3Ka, PI3Kalpha, PI3Kinasealpha, GSK1059615, PI3-kinases, phosphoinositide, 3, kinases, Tocris Bioscience, PI 3-kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitorrac-CCT 250863
Potent Nek2 inhibitorRoscovitine
Potent, selective cyclin-dependent kinase inhibitorEnzastaurin
Potent PKCβ inhibitorBMS 265246
Potent cdk1/2 inhibitorAutocamtide-2-related inhibitory peptide, myristoylated
CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptideMP A08
Selective ATP competitive SphK1 and 2 inhibitor; cell permeableAkti-1/2
Potent and selective dual Akt1 and 2 inhibitor
December 3 - 7, 2016
San Francisco, CA,